Cannabis Stock Gainers And Losers From July 23, 2019

0
66
This post was originally published on this site

Read more about our latest Cannabis News! CANNABIS HOME

Gainers

Never miss a news story in the cannabis world. Click here to check out Benzinga Cannabis for more.

Losers

  • Aurora Cannabis (NYSE: ACB) shares tumbled by 0.89%, closing at $6.67.
  • Aphria (NYSE: APHA) shares fell 0.0% to close at $6.17.
  • CannTrust Holdings (NYSE: CTST) shares fell 4.03% to close at $2.62.
  • Curaleaf Holdings (OTC: CURLF) shares fell 7.27% to close at $7.40, trading lower after FDA issued an open warning letter on CBD products.
  • Greenlane Holdings (NASDAQ: GNLN) shares fell 1.04% to close at $7.61.
  • GW Pharmaceuticals (NASDAQ: GWPH) shares fell 1.03% to close at $161.43.
  • HEXO (NYSE: HEXO) shares fell 4.03% to close at $4.52.
  • India Globalization Cap (AMEX: IGC) shares tumbled by 3.76%, eventually closing at $1.28.
  • Innovative Industrial (NYSE: IIPR) shares fell 8.94% to close at $103.03.
  • iAnthus Capital Holdings (OTC: ITHUF) shares dropped by 7.3%, to close at $2.54.
  • MedMen Enterprises (OTC: MMNFF) shares fell 1.84% to close at $2.03.
  • New Age Beverages (NASDAQ: NBEV) shares fell 4.07% to close at $3.54.
  • OrganiGram Holdings (NASDAQ: OGI) shares tumbled by 3.19%, eventually closing at $6.07.
  • Pyxus International (NYSE: PYX) shares fell 4.86% to close at $13.69.
  • cbdMD (AMEX: YCBD) shares fell 0.75% to close at $3.97.
  • Zynerba Pharmaceuticals (NASDAQ: ZYNE) shares tumbled by 8.72%, eventually closing at $11.10.

Never miss a news story in the cannabis world. Click here to check out Benzinga Cannabis for more.

Related Stories:

Harris, Nadler Introduce Comprehensive Federal Cannabis Reform Bill

WeedMD Rolls Out Cannabis Extraction Subsidiary

Every Major Legislative Win Related To Cannabis Is Included In The Marijuana Policy Project’s 2019 Report

Stock chart: 

Read more about our latest Cannabis News! CANNABIS HOME

© 2019 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.